Definium Therapeutics, Inc.
DFTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.44B
Close$
$2.89
92.5% downside
Current Fair Value
92.5% downsideOvervalued by 92.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.44 Billion |
|---|---|
| Enterprise Value | $4.78 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.06 |
| Beta | 2.26 |
| Outstanding Shares | 110,684,720 |
Return
| Return on Equity | -38.51% |
|---|---|
| Return on Assets | -31.79% |
| Return on Invested Capital | -23.56% |
Valuation & Multiples
| P/E Ratio | -11.91 |
|---|---|
| PEG | -4.38 |
| Price to Sales | - |
| Price to Book Ratio | 4.81 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -21.25 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3988▲ 17.34% |
|---|---|
| Total Calls | 3,446,000▲ 125.02% |
| Total Puts | 1,374,100▲ 298.17% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 111.96%▲ 40.23% |
|---|---|
| Total Invested | $5.52B▲ 274.57% |
| Investors Holding | 387▲ 127.00% |
ESG Score
No data
About Definium Therapeutics, Inc.
74 employees
CEO: Robert Barrow Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized...